key: cord-1029291-twu8sfnh
authors: Brox, Regine; Achenbach, Susanne; Hackstein, Holger
title: Detection of SARS‐CoV‐2‐independent immunoregulatory activity of COVID‐19 convalescent plasma
date: 2021-10-08
journal: Transfusion
DOI: 10.1111/trf.16685
sha: dea13376b9ffdc21433a6575f1227fd86961e132
doc_id: 1029291
cord_uid: twu8sfnh

BACKGROUND: Convalescent plasma has emerged as a potential specific treatment for coronavirus disease 2019 (COVID‐19), since it contains severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies. Several studies are currently investigating the efficacy of convalescent plasma for treatment of COVID‐19, with a focus on neutralizing antibodies. However, there is little information on whether convalescent plasma may contain additional immunoregulatory constituents produced by the blood donor during convalescence. Therefore, using a standardized whole blood assay employing synthetic toll‐like receptor (TLR) ligands, we have investigated the immunoregulatory capacity of convalescent plasma in direct comparison to ABO‐matched allogeneic control plasma. STUDY DESIGN AND METHODS: Whole blood samples from healthy blood donors were collected, and autologous plasma was replaced by convalescent plasma or ABO‐matched control plasma. Standardized innate immune triggering and monitoring was performed by adding different TLR ligands (Pam3CsK4 [TLR1/2], HKLM [TLR2], LPS [TLR4], flagellin [TLR5], ssRNA40 [TLR8], imiquimod [TLR7], and FSL‐1 [TLR2/6]) and subsequent quantitative analysis of pro‐ and anti‐inflammatory cytokines (IP‐10, IL‐1β, TNF‐α, MCP‐1, IL‐6, IL‐10, and IFN‐γ) by cytometric bead array. Negative controls included unstimulated samples as well as samples spiked with autologous plasma. RESULTS: COVID‐19 convalescent plasma (CCP) significantly decreased pro‐inflammatory cytokines production triggered by different TLR ligands in healthy donors as compared with healthy control plasma. IL‐6, MCP‐1, and IFN‐γ represented the cytokines that are most frequently downregulated by convalescent plasma. CONCLUSION: Our experiments reveal a potential novel, SARS‐CoV‐2‐independent immunomodulatory activity of CCP, which may be beneficial for COVID‐19 patients.

Owing to the current coronavirus disease 2019 (COVID- 19) pandemic, which accounts for more than 150 million infections and 3 million deaths worldwide, there is a high demand for treatment options. 1 COVID-19 convalescent plasma (CCP), plasma collected from patients who have recovered from COVID-19, offers a potential therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2 Historical evidence suggests the potential of convalescent plasma transfusions to improve the clinical course of different viral infectious diseases, such as influenza, 3 ebola, 4 SARS, 5 and Middle East respiratory syndrome (MERS) 6 with varying degrees of success. Current studies indicate that convalescent plasma collected from patients who have recovered from COVID-19 contains antibodies to SARS-CoV-2 that can be passively transferred to the plasma recipient and might protect against a severe course of the disease. 7, 8 However, evidence supporting the use of convalescent plasma as a therapeutic strategy against COVID-19 remains inconclusive due to a high variability in selection criteria for donors and bestsuited recipients, effective titers of neutralizing antibodies, and optimal timing of administration. 9 Randomized and controlled clinical trials evaluating the effectiveness and safety of CCP are ongoing. 10 While more attention has been focused on direct antiviral activity of SARS-CoV-2 antibodies in convalescent plasma, plasma contains a large variety of immunomodulatory components including cytokines, clotting factors, hormones, natural antibodies, and other proteins, which may interfere with the antiviral and anti-inflammatory immune response. 11, 12 We hypothesized that during convalescence from COVID-19 infection, the production of potential immunomodulatory plasma factors may have been enhanced and could contribute to its clinical effectiveness.

Therefore, we used an in vitro whole blood assay employing synthetic toll-like receptor (TLR) ligands and healthy donor WBCs to address the question of whether CCP has SARS-CoV-2-independent immunomodulatory effects.

To investigate the immunomodulatory effects of CCP, we used a standardized whole blood assay as a simple model for infection-induced inflammation. Stimulation of various TLRs, a family of pattern recognition receptors, serves as an ideal experimental model for infections since the first line of defense against pathogens is simulated, thereby bridging innate and adaptive immunity by the activation of antigen-presenting cells and the release of inflammatory cytokines. 13 The diversity of TLR ligands, which are derived from bacteria, viruses, or synthetic origin, offers the possibility of examining CCP in different immunological contexts. Before TLR stimulation, plasma from healthy donors was replaced: (1) by their own plasma (autologous plasma control), (2) by plasma from other healthy donors (healthy plasma control), or by CCP from fully recovered donors.

After obtaining written informed consent, freshly drawn peripheral blood from healthy donors aged 18-60 years was anticoagulated using tri-sodium citrate monovettes (S.Monovette, Sarstedt). All CCP donors were healthy and donated plasma according to the Paul Ehrlich Institute (Federal Institute for Vaccines and Biomedicine, Germany) recommendations as early as 4 weeks after complete recovery from COVID-19 or 2 weeks after their last negative SARS-CoV-2 PCR diagnosis. SARS-CoV-2 immunoglobulin G (IgG) antibodies in the convalescent plasma and healthy plasma controls were measured by a semi-quantitative enzyme-linked immunosorbent assay (LIAISON ® SARS-CoV-2 S1/S2 IgG, DiaSorin, Germany) with a defined cutoff of 15 AU/ml. The study was approved by the local ethics committee of University Hospital Erlangen (346_18B, 343_18B, 357_19B). Blood samples were kept at room temperature for no longer than 2 h before processing.

The plasma was obtained from whole blood of healthy donors and CCP donors by centrifugation for 10 min at 1000 Â g and the supernatant was stored at À20°C until use. To investigate the immunomodulatory effect of CCP in healthy donors, plasma from the whole blood of healthy donors was replaced after centrifugation with either the same amount of CCP or ABOmatched control plasma from other healthy donors (healthy plasma control). The plasma used for replacement was ABO compatible, and replacement with the autologous plasma (autologous plasma control) served as a reference.

Monitoring of immunomodulatory response was performed adapting an in vitro whole blood assay. 14 After plasma replacement, the whole blood diluted 1:2 with RPMI 1640 (Sigma-Aldrich) supplemented with 1% penicillin/streptomycin (Sigma-Aldrich) and 2 mM L-glutamine (Gibco) were distributed in 96-well round bottom plates (total volume 200 μl/well). Samples were stimulated for 18 h in 5% CO 2 at 37°C with 20 μl TLR ligands from InvivoGen including 500 ng/ml Pam3CsK4 (TLR1/2), 10 8 cells/ml HKLM (TLR2), 10 ng/ml LPS E. coli K12 (TLR4), 1 μg/ml flagellin-ST (TLR5), 100 ng/ml FSL-1 (TLR6/2), 5 μg/ml imiquimod (TLR7), 2.5 μg/ml ssRNA40/LyoVec (TLR8), or vehicle. The supernatant was collected and frozen at À20°C until analysis.

Cytokines including interferon-induced protein (IP)-10, interleukin (IL)-1β, tumor necrotic factor (TNF)-α, monocyte chemoattractant protein-1 (MCP-1), IL-6, IL-10, and interferon gamma (IFN-γ) were quantified by flow cytometry bead-based immunoassay (LEGENDplexTM human essential immune response panel, BioLegend) according to the manufacturer's protocol and analyzed using LEGENDplex version 7.0 software (Vigene Tech).

Data were reported as mean ± SD unless otherwise stated. Statistical analysis was performed with GraphPad Prism version 8.3.0 (GraphPad Software, San Diego, California USA). Statistical significance between groups was evaluated by Mann-Whitney U test. p value <.05 was considered statistically significant.

The average SARS-CoV-2 IgG antibody level in convalescent plasma was 67 ± 29 AU/ml, and all 12 CCP donors had recovered from asymptomatic COVID-19 infection. In contrast, none of the healthy control plasma were positive for SARS-CoV-2 IgG antibodies with values <3.80 AU/ml. An essential immune response panel of seven cytokines (IP-10, IL-1β, TNF-α, MCP-1, IL-6, IL-10, and IFNγ) was evaluated, and the results revealed a distinct cytokine profile triggered by the TLR ligands in the autologous plasma control group ( Table 1 ). The unstimulated CCP and healthy plasma control samples showed no measurable cytokine levels (Table S1) .

To elucidate the immunomodulatory effect of CCP in comparison with the healthy plasma control, the cytokine release of these two groups was normalized to the respective autologous plasma control group (Figure 1 ). This analysis showed that replacement by CCP in healthy donors significantly downregulated a variety of cytokines following the TLR stimulation, as compared with the healthy plasma control. IL-1β, IL-6, and IL-10 levels were 1.5-2-fold lower in the CCP group than in the healthy plasma control group following stimulation with Pam3CsK4 ( Figure 1A ). Replacement by CCP induced a significant decrease of IL-10 and IFN-γ in HKLMstimulated healthy donor cells compared with the plasma control group ( Figure 1B ). Following stimulation with LPS, several cytokines, including IL-1β (1.4-fold), TNF-α (2-fold), MCP-1 (1.6-fold), IL-6 (1.3-fold), and IFN-γ (2.3-fold), were reduced by CCP ( Figure 1C ). Compared with the healthy control plasma, we observed a decline in the release of IL-1β, TNF-α, and IFN-γ following stimulation with Flagellin after replacement by CCP ( Figure 1D) , whereas for ssRNA40, the amount of MCP-1, IL-6, and IFN-γ was markedly decreased ( Figure 1E ). Approximately 1.5-fold less MCP-1 and IL-6 were detected between the CCP group and the healthy control plasma group in imiquimod-stimulated whole blood ( Figure 1F ) and also lower levels of MCP-1 were induced by CCP following stimulation with FSL-1 ( Figure 1G ). Interestingly, MCP-1, IFN-γ, and IL-6 were most consistently inhibited by CCP.

To investigate the influence of the severity of COVID-19 disease on TLR-stimulated cytokine release, CCP donors were divided into moderate and severe disease group based on whether they were hospitalized or not ( Figure 2 ). We found no association between the severity of COVID-19 infection and suppression of TLRstimulated cytokine release.

Since convalescent plasma is currently used to treat severely ill COVID-19 patients, our results highlight that CCP may have an immunomodulatory effect that is SARS-CoV-2 antibody independent. Herein, we report that CCP significantly suppresses the release of various cytokines in healthy donors, and this inhibitory effect can be demonstrated across different TLR receptors and linked signaling pathways. Based on the pattern of our results, we identified IL-6, MCP-1, and IFN-γ as the most frequently downregulated cytokines, following stimulation with different TLR ligands. IL-6 is an important pleiotropic cytokine whose production is related to T A B L E 1 Cytokine release of autologous plasma control following different toll-like receptor stimulation (n = 3, ±SD) F I G U R E 1 COVID-19 convalescent plasma (CCP) shows immunomodulatory effects on toll-like receptor (TLR)-triggered cytokine release. Cytokine release after plasma replacement by CCP (black) and healthy plasma control (HP; gray) following different TLR stimulation are represented as fold change of autologous plasma control levels, with n = 12 convalescent plasma, each performed in duplicates (A-G). Comparisons were made using the Mann-Whitney U test and differences were significant at p < .05 (*) and .01 (**). ND = not determined due to low cytokine levels bacterial and viral infections, since it controls the differentiation of monocytes, increases B-cell IgG production, and promotes Th2 response. 15,16 MCP-1 is a potent monocyte-attracting chemokine that orchestrates the migration of myeloid and lymphoid cells during immune defense. 17 IFN-γ, which is normally produced during infection, is one of the most characteristic cytokines that are suggested to be essential in the fine-tuning and control of the extent of inflammatory conditions. 18 Interestingly, recent studies have also shown that increased levels of IL-6, MCP-1, and IFN-γ, among other cytokines, have been detected in COVID-19 patients under intensive care and found to correlate with clinical parameters and severity of the disease. [19] [20] [21] Early detection of cytokine storm and immediate initiation of treatments to reduce severity are both essential for the treatment of severe COVID-19. Thus, great efforts are being made to find an appropriate anti-inflammatory therapy. The application of therapeutic plasma exchange (TPE) and the use of convalescent plasma have both been suggested to reinforce immunity and provide the chance of overcoming sepsisinduced cytokine storm. 22 In a case report that described the beneficial effects of TPE on COVID-19, after plasma exchange, the patient showed clinical improvement with reduced inflammatory markers including IL-6. 23 Although a randomized clinical trial, evaluating the immunomodulatory effect of CCP on COVID-19-related cytokine storm, found no significant improvement of mortality rate and length of in-hospital stay, convalescent plasma therapy significantly decreased the mean levels of IL-6, TNF-α, and IFN-γ. 24 In addition, it is supposed that plasma from healthy donors provides immunomodulatory effects via the infusion of anti-inflammatory cytokines and antibodies that blockade complement, inflammatory cytokines, and auto-antibodies. 25 The results of cytokine release after plasma replacement by CCP were grouped into moderate (black) and severe course of disease (gray) following different TLR stimulation, with n = 12 convalescent plasma, each performed in duplicates (A-G). Comparisons were made using the Mann-Whitney U test and differences were significant at p < .05 (*) and .01 (**). ND = not determined due to low cytokine levels While our finding regarding the decreased cytokine production following the replacement by CCP in our in vitro model for different pathogen-induced inflammation is notable, it remains unclear whether these effects are relevant enough to translate to a clinically improved outcome. Synthetic TLR ligands can serve as in vitro tool to investigate different immunological signaling pathways by stimulating whole blood in a reproducible and standardized manner and may help to design appropriate clinical trials that are necessary to determine the clinical relevance. However, a recent two-phase controlled study demonstrated that CCP attenuated the exhausted phenotype and increased memory T-and B-lymphocytes together with a reduction of IL-6/IFN-γ and IL-6/IL-10 ratios compared with those who received standard therapy alone. 21 Although our whole blood assay is optimal to monitor immunomodulatory effects by incorporating all immune cells and the microenvironment, further studies using peripheral blood mononuclear cells or TLRexpressing cell lines could be useful to unravel the molecular mechanism and signal transduction events that lead to the observed downregulation of cytokines. To gain more information about the immunomodulatory factor in the CCP, further experiments can be performed to investigate, for example, whether it is a protein or a lipid or whether it is heat stable. Additional immunological readouts to measure innate immune cell function, including phagocytosis, chemotaxis, and expression of surface molecules, may further reveal the immunomodulatory effects. Herein, we focused on cytokine production because it is also used as a readout in clinical trials for adverse outcomes in critically ill patients. 21 In conclusion, using a standardized whole blood assay and appropriate negative controls, we demonstrated that CCP has an inhibitory effect on cytokine release triggered by different TLR ligands in healthy donors as compared with healthy control plasma. In addition to the effects of neutralizing antibodies, CCP may therefore exhibit additional immunoregulatory properties. Due to the pleiotropic nature of cytokines, the use of CCP may either be beneficial in states of hyperinflammation, which is being manifested in a cytokine storm, or detrimental in states of immunodeficiency.

An interactive web-based dashboard to track COVID-19 in real time

The convalescent sera option for containing COVID-19

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Evaluation of convalescent plasma for Ebola virus disease in Guinea

Use of convalescent plasma therapy in SARS patients in Hong Kong

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience

Manufacturing of convalescent plasma of COVID-19 patients: aspects of quality

Convalescent plasma antibody levels and the risk of death from Covid-19

Why will it never be known if convalescent plasma is effective for COVID-19

A scoping review of registered clinical trials of convalescent plasma for COVID-19 and a framework for accelerated synthesis of trial evidence (FAST evidence)

Plasma components: properties, differences, and uses

Convalescent plasma in Covid-19: possible mechanisms of action

Toll-like receptors activation, signaling, and targeting: an overview

Whole blood cytokine response as a measure of immunotoxicity

The role of interleukin 6 during viral infections

Interleukin-6 in bacterial infection and sepsis: innocent bystander or essential mediator?. Yearbook of Intensive Care and Emergency Medicine 1999. Yearbook of Intensive Care and Emergency Medicine

Monocyte chemoattractant protein-1 (MCP-1): an overview

Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

COVID-19 convalescent plasma composition and immunological effects in severe patients

Immunopathogenesis and treatment of cytokine storm in COVID-19

Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19

A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm

Intravenous immunoglobulin in neurology-mode of action and clinical efficacy

SUPPORTING INFORMATION Additional supporting information may be found in the online version of the article at the publisher's website. How to cite this article

We thank all voluntary blood donors for providing blood samples at the Department of Transfusion Medicine and Hemostaseology, University Hospital Erlangen and all colleagues involved for supporting this study. This work was supported by SFB Transregio 84 Project A2 (to H.H). Open Access funding enabled and organized by Projekt DEAL.

The authors have disclosed no conflicts of interest.ORCID Regine Brox https://orcid.org/0000-0003-3104-4869 Holger Hackstein https://orcid.org/0000-0001-9722-8180